Ann Arbor, Michigan., – July 20, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the release of a behind the scenes look into its silkworm breeding facility in Vietnam. This video is the first in a series designed to bring the viewer inside the Company’s recombinant spider silk production operations. 

This video tour edition highlights the breeding and egg production center that the Company established in Vietnam, to support in-house and third-party contract manufacturing of its eco-responsible and cost-effective spider silk.

Operated by its wholly owned Vietnamese subsidiary, the Company believes that this facility is now equipped to meet the production demand for its proprietary specialized spider silk silkworm eggs through 2025 and has the capacity to expand far beyond that.

“Our team has built out what we believe to be one of the most advanced silkworm breeding facilities in the world. We are excited to share these first behind-the-scenes looks into our operations and to bring the viewers along on this incredible journey bringing our eco-responsible cost-effective spider silk to the global consumer markets,” said Company COO Jon Rice.

Interested viewers can find the video at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/qeM2hzXbtRM, where they can subscribe to be notified of future video releases in this series.

In upcoming video releases, the Company expects to bring viewers along for tours inside the R&D and quality control labs as well as the feeding, rearing, and breeding operations.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI – June 27, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that, in collaboration with its joint venture partner Kings Group, the Company has selected a high-quality garment manufacturer to produce Spydasilk’s^TM first apparel line.

Over the course of multiple meetings between Kraig Labs, Kings Group, and the garment manufacturer, conducted while the Company’s COO was in Vietnam this month, the Company finalized its manufacturer choice for the first apparel launch under the Spydasilk^TM brand. 

The manufacturer selected has demonstrated its capacity and technical ability to deliver on Spydasilk’s vision for apparel that blends performance and elegance with its exclusive spider silk materials. With more than 20 years in business and its strong ties to Vietnam’s entire textile supply chain, this producer can leverage the capabilities of the best mills to bring the Spydailk brand to life. 

In partnership with Kings Group, the Company has already delivered its recombinant spider silk yarn and a non-spider silk fabric swatch for use in developing a brand new fabric built upon the performance and feel of the Company’s spider silk.

“Bringing the first products built on our spider silk technology to life is a critical step we are taking simultaneously with our planned increase in production through third-party contractors,” said Company COO, Jon Rice. “The network we have assembled to launch Spydasilk brings together top textile science, fashion, marketing, and branding experts. Our vision for the mass production and distribution of products built upon the amazing capabilities of spider silk is now quickly becoming a reality.”

Kraig Labs and Kings Group are simultaneously developing an accelerated product launch plan, including media, marketing, sales, and distribution systems for this first direct-to-consumer apparel launch.

The Company expects to continue to provide additional details and updates on the rapid advancements it is making under its business plan. Further information will be shared in press releases on advancements in production, quality control, and end market products over the coming days and weeks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Labs Launches the Critical Next Phases of its Business Plan, Expanded Recombinant Spider Silk Production in Collaboration with Third-Party Contractors

Ho Chi Minh City, Vietnam – June 21, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the completion of its third-party pilot production. As a result of this highly successful program, Kraig Labs will launch the critical next phases of its business plan and expand its recombinant spider silk production in collaboration with third-party contractors.

Key Kraig Labs management team members traveled to Vietnam to review the results of a series of pilot production runs completed by one of the silk production subcontractors the Company has been working with in preparation for entering the next phase of its business plan. The subcontractor pilot program exceeded management’s expectations to the point that Kraig Labs is now finalizing the terms of a 5-year production contract. This joint effort, by the subcontractor and Prodigy Textiles, the Company’s Vietnamese subsidiary, has already completed production of the raw recombinant spider silk needed for the first apparel launch under the Company’s jointly owned apparel brand, Spydasilk^TM.

Kraig Labs is on track to complete negotiations on the structure of expanded production with this contractor before Jon Rice, the Company’s Chief Operations Officer, returns to the US this week. Based on the results of these first pilot runs and the contractors’ production capacity, the Company is now on a path to producing metric tons of spider silk.

During this trip, the Company’s top scientist has also been evaluating and updating production and science processes at Prodigy Textiles. A focus of his work has been bringing state-of-the-art technology into our Vietnamese lab to reduce and eliminate mundane silkworm pathogens known to impact global silk production and inhibited the Company’s production growth. Our facility is now one of the most advanced sericulture labs in South East Asia and is already enhancing the quality of our operations.

The management team traveled over 2,700 miles since arriving in Vietnam. The Company met with three separate contract manufacturers, spanning from Da Nang to Ho Chi Minh City, who are vying to produce the Company’s specialized silk.

“The production capabilities demonstrated by the contract producer in these first runs have given us the raw spider silk necessary to bring our first finished garments to market and the confidence to aggressively push forward for exponential increases in silk output. With these successes, we are entering the next phase of our business plan, which includes rapid production expansion with subcontractors in parallel with the growth of our nascent joint venture apparel brand. Together, our teams from Kraig, Prodigy Textiles, and Spydasilk^TM are showing significant and tangible success on all fronts,” stated Rice

Kraig Labs anticipates issuing a series of additional updates on production expansion, Prodigy Textile’s laboratory developments, Spydasilk^TM, and other significant achievements shortly after the management team returns to the Company’s headquarters this week. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Management’s crowded Agenda includes meetings with Governmental Officials and intensive Factory Team Training

ANN ARBOR, Mich., – June 8, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, sends senior members of its US management and research team to Vietnam to support multiple aspects of operations focused on production expansion and development of end markets.

This trip marks the return to normal travel and the participating management team members have a packed agenda for this trip, following the lifting of travel restrictions.

Jon Rice, the Company’s Chief Operations Officer, will be traveling throughout Vietnam to support Kraig Labs’ production expansion and commercialization on several fronts. Rice will be meeting with government officials in multiple provinces to discuss additional lands for production and secure support for the further expansion of the Company’s spider silk technologies. He will hold a series of meetings with a contract silk manufacturer with the goal of securing an agreement for 3^rd party silk production. In previous discussions, this manufacturer already outlined a production scale-up plan to produce as much as 200 metric tons of silk per year. Another key goal for this trip will be meetings with Kraig Labs’ joint venture partners, PL Kings, and finalizing plans for the initial product launch under the Spydasilk brand. Rice plans to review textile mills under consideration for the production of the first recombinant spider silk fabric under the Spydasilk brand.

“This is a timely and much-needed trip that will allow us to make the best onsite decisions for Prodigy’s existing operations and the numerous potential expansion opportunities ahead. We’re also excited to bring our US and Vietnam teams together to meet the Company’s evolving needs and address, in person, a diverse list of items that will set the direction of Kraig Labs’ next growth phase,” stated Rice.

The Company is sending its senior scientist, Dr. Miller, to transfer additional process control technologies to the newly formed lab team at Prodigy Textiles, the Company’s wholly-owned Vietnamese subsidiary. Dr. Miller will provide hands-on training for the implementation of several key production initiatives, including the installation of additional laboratory and production equipment, and transferring additional R&D technology. Dr. Miller will devote the majority of his time and efforts to working with new genetic screening protocols and auditing current production processes.

“Dr. Miller’s focus will be on aligning the Prodigy laboratory team members’ efforts with his vision for the laboratory and its role in supporting production growth. This will ensure that the lab team members are optimally trained and positioned to support the production team and cement Prodigy as the top silkworm breeding facility in Vietnam,” concluded Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 27, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has kicked off the first production run of the second quarter for its recombinant spider silk.

In support of the growing production capacity at the Company’s subsidiary, Prodigy Textiles, the laboratory team has dramatically increased the testing throughput. This quality testing is the bedrock upon which the Company has been growing its spider silk production operations. Once the team completes this testing cycle, it will have increased its throughput by nearly ten times that of Q1 2022.

This milestone marks a new baseline for production capacity and sets the Company on a trajectory to outgrow its existing factory capacity as early as Q2 2023. Outpacing the capacity of the existing factory space was anticipated and planning for additional production capacity is well underway.

“The groundwork for this capacity increase was laid with investments made at Prodigy in 2021,” said Company COO Jon Rice. “The leadership and team that we have put in place at Prodigy continue to hit their marks, and our investments in equipment and personnel are delivering the rewards we envisioned. I expect that we will have many exciting updates on Prodigy and the commercialization of our eco-friendly and cost effective spider silk in the coming months.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Company is in its strongest financial position ever, having raised $8 million in 16 months

ANN ARBOR, Mich., – April 14, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has received another $1.5 million from YAII PN, Ltd (“YAII”) a fund managed by Yorkville Advisors Global, LP (“Yorkville”). The $1.5 million received this week is the second half of a $3 million fund agreement signed with YAII in January 2022. This $3 million and those from the previously announced transactions account for an $8 million total YAII investment into Kraig Labs over the past 16 months.

The Company is well underway, putting this impact capital to work, strengthening its production operations. Over the last nine months, the Company has deployed capital to build additional production capacity and bring key onsite quality control systems online. These renovations included building out custom-designed rearing rooms, purchasing and installing custom automated production equipment, and planting onsite mulberry to support year-round operations. This work also included the construction of a fully operational molecular biology laboratory that provides onsite and in-process quality control, mirroring the capabilities of the Company’s U.S.-based R&D labs.

“This capital is allowing us to make strategic investments in critical processing, facilities, and equipment that have dramatically enhanced our production capabilities and capacity. Prodigy Textiles is now fully operational and beginning to fulfilling its mission of bringing eco-responsible and cost-effective spider silk to the global textile markets,” said Company COO, Jon Rice.

Maxim Group LLC acted as the sole placement agent for this capital raise.

The Company thanks Maxim Group LLC and Yorkville for their continued trust and confidence in Kraig Labs and its disruptive innovation of the technical textile markets.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com